An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists

Urology

Volumn 62, Issue 5, 2003, Pages 877-882

  Koch, Michael ^a   Steidle, Christopher ^b   Brosman, Stanley ^b   Centeno, Arthur ^b   Gaylis, Franklin ^b   Campion, Marilyn ^b   Garnick, Marc B ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ANTINEOPLASTIC AGENT; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PAIN; CANCER STAGING; CANCER SURGERY; CASTRATION; CLINICAL TRIAL; COMORBIDITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HEMATOCRIT; HEMOGLOBINOPATHY; HUMAN; HYDRONEPHROSIS; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; OPEN STUDY; ORCHIECTOMY; PERIPHERAL NERVE; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SPINAL CORD COMPRESSION; SYMPTOM; TREATMENT FAILURE; TREATMENT OUTCOME; UREMIA; URETER CATHETERIZATION; URINARY TRACT OBSTRUCTION;

EID: 0242664216     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(03)00656-3     Document Type: Article

References (10)

1. Paulson D.F. The role of endocrine therapy in the management of prostatic cancer. Skinner D.G., deKernion J.B. Genitourinary Cancer. 1978;388-396 WB Saunders, Philadelphia.
2. Chrisp P., Sorkin E.M. Leuprorelin a review of its pharmacology and therapeutic use in prostatic disorders. Drugs Aging. 1:1991;487-509.
3. Schulze H., Senge T. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate. J Urol. 144:1990;934-941.
4. Thompson I.M., Zeidman E.J., Rodriguez F.R. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol. 144:1990;1479-1480.
5. Lupron depot, 7.5 mg, in Physician's Desk Reference. Montvale, New Jersey, Medical Economics Company, 2001, vol 55, pp 3180-3182.
6. Garnick M.B., Campion M.S. Abarelix depot, a GnRH antagonist, v LHRH superagonists in prostate cancer differential effects on follicle-stimulating hormone. Mol Urol. 4:2000;275-277.
7. Tomera K., Gleason D., Gittleman M., et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol. 165:2001;1585-1589.
8. McLeod D., Zinner N., Tomera K., et al. A phase III, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology. 58:2001;756-761.
9. Trachtenberg J., Gittleman M., Steidle C., et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 167:2002;1670-1674.
10. Gonzalez-Barcena D., Vadillo-Buenfil M., Gomez-Orta F., et al. Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate. 24:1994;84-92.